Incidence of hip and subtrochanteric/femoral shaft fractures in postmenopausal women with osteoporosis in the phase 3 long-term odanacatib fracture trial
| Autor: | José Fernando Molina Restrepo, Socrates E. Papapoulos, Arthur C. Santora, Rachid Massaad, Anne E. de Papp, Toshitaka Nakamura, Michael R. McClung, D Cohn, Henry G. Bone, David W. Dempster, Mary L. Bouxsein, Felicia Cosman |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Endocrinology Diabetes and Metabolism Osteoporosis 030209 endocrinology & metabolism biochemical markers of bone turnover Placebo 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Double-Blind Method Bone Density medicine therapeutics Humans Orthopedics and Sports Medicine Femur Cumulative incidence Osteoporosis Postmenopausal Aged Femoral neck Bone mineral clinical trials Bone Density Conservation Agents Femur Neck Hip Fractures business.industry Incidence Biphenyl Compounds Hazard ratio medicine.disease osteoporosis Surgery Postmenopause 030104 developmental biology medicine.anatomical_structure chemistry Female business Odanacatib |
| Zdroj: | Journal of Bone and Mineral Research Journal of Bone and Mineral Research, 36(7), 1225-1234. WILEY |
| Popis: | We prospectively assessed, with predefined criteria, the location and rates of all femur fractures (hip, subtrochanteric/femoral shaft [ST/FS], including atypical [AFF] and distal fractures) in women at increased fracture risk during treatment with the cathepsin K inhibitor, odanacatib (ODN), or placebo over 5 years in the Long-Term ODN Fracture Trial (LOFT and LOFT Extension [NCT00529373, EudraCT 2007-002693-66]). ODN was an investigational antiresorptive agent previously in development as an osteoporosis treatment that, unlike bisphosphonates, reduces bone formation only transiently. Women aged >= 65 years with a bone mineral density (BMD) T-score |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|